Belerophon Therapeutics (Nasdaq: BLPH) reported positive results from the final analysis of a Phase 2 long-term extension study of INOpulse to treat pulmonary arterial hypertension sending the stock price soaring 85 cents to $2.83.
Belerophon Therapeutics reports positive study results
February 09, 2016 at 12:02 PM EST
